ABSTRACT The prompt rollout of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine is facilitating population immunity, which is becoming more dominant than natural infection-mediated immunity. In the midst of coronavirus disease 2019 (COVID-19) vaccine deployment, understanding the epitope profiles of vaccine-elicited antibodies will be the first step in assessing the functionality of vaccine-induced immunity. In this study, the high-resolution linear epitope profiles of Pfizer-BioNTech COVID-19 mRNA vaccine recipients and COVID-19 patients were delineated by using microarrays mapped with overlapping peptides of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. The vaccine-induced antibodies targeting the RBD had a broader distribution across the RBD than that induced by the natural infection. Half-maximal neutralization titers were measured in vitro by live virus neutralization assays. As a result, relatively lower neutralizability was observed in vaccine recipient sera, when normalized to a total anti-RBD IgG titer. However, mutation panel assays targeting the SARS-CoV-2 variants of concern have shown that the vaccine-induced epitope variety, rich in breadth, may grant resistance against future viral evolutionary escapes, serving as an advantage of vaccine-induced immunity. IMPORTANCE Establishing vaccine-based population immunity has been the key factor in attaining herd protection. Thanks to expedited worldwide research efforts, the potency of mRNA vaccines against the coronavirus disease 2019 (COVID-19) is now incontestable. The next debate is regarding the coverage of SARS-CoV-2 variants. In the midst of vaccine deployment, it is of importance to describe the similarities and differences between the immune responses of COVID-19 vaccine recipients and naturally infected individuals. In this study, we demonstrated that the antibody profiles of vaccine recipients are richer in variety, targeting a key protein of the invading virus, than those of naturally infected individuals. Vaccine-elicited antibodies included more nonneutralizing antibodies than infection-elicited antibodies, and their breadth in antibody variations suggested possible resilience against future SARS-CoV-2 variants. The antibody profile achieved by vaccinations in naive individuals provides important insight into the first step toward vaccine-based population immunity.
【저자키워드】 COVID-19, SARS-CoV-2, Neutralizing antibodies, spike, serology, Spike protein, RBD, immunoserology, 【초록키워드】 coronavirus disease, antibodies, Resilience, Coronavirus disease 2019, Vaccine, coronavirus, COVID-19 vaccine, immune response, vaccination, Mutation, Immunity, antibody, mRNA vaccine, Variation, variants of concern, peptide, Microarrays, in vitro, severe acute respiratory syndrome Coronavirus, virus, Spike protein, Receptor binding domain, mRNA vaccines, Protein, Coverage, Viral, SARS-CoV-2 variants, immune responses, sera, SARS-CoV-2 spike protein, Research, peptides, Microarray, population immunity, respiratory, distribution, natural infection, epitope, Pfizer-BioNTech, COVID-19 patients, Live virus, breadth, Vaccinations, Vaccine-induced immunity, similarity, COVID-19 patient, High-resolution, Anti-RBD IgG, overlapping, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, profile, vaccine-induced antibodies, infected individuals, naïve individuals, individual, potency, similarities, key factor, neutralization titer, recipient, neutralization assays, dominant, shown, linear, provide, variety, demonstrated, suggested, the RBD, mapped, were measured, Establishing, normalized, the SARS-CoV-2, vaccine-induced antibody, 【제목키워드】 Spike protein, mRNA, mapping, recipient,